SML3059

Lacosamide

≥98% (HPLC), sodium channel modulator, powder

• Synonim(y): (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide, ADD 243037, ADD-243037, ADD243037, Erlosamide, LCM, SPM-927, SPM927
• Wzór empiryczny (zapis Hilla): C₁₃H₁₈N₂O₃
• Numer CAS: 175481-36-4
• Masa cząsteczkowa: 250.29
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Nazwa produktu: Lacosamide, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• optical activity: [α]/D 13 to 18° (C=0.5g/100mL, MeOH)
• drug control: USDEA Schedule V
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: N([C@H](COC)C(=O)NCc1ccccc1)C(=O)C
• InChI: 1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
• InChI key: VPPJLAIAVCUEMN-GFCCVEGCSA-N

Opis

Biochem/physiol Actions

Lacosamide is an orally active anticonvulsant that blocks voltage-gated sodium channels (VGSCs) selectively in their inactivated state (IC50 = 16 μM/Nav1.8, 182 μM/Nav1.7, 415 μM/Nav1.3) over resting state by enhancing slow inactivation. In addition to in vivo anticonvulsant activity (ED50 = 4.5 mg/kg in mice via i.p., 3.9 mg/kg in rats via p.o. by maximal electroshock seizure test), lacosamide also shows therapeutic efficacy in various pain models (10-30 mg/kg in rats via i.p.).

Orally active anticonvulsant that blocks voltage-gated sodium channels (VGSCs) selectively in inactivated over resting state by enhancing slow inactivation.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable